Skip to main content

Biofrontera Inc.

corporate_fare Company Profile

Biofrontera Inc.

BFRI·NASDAQ·Life Sciences·CIK 0001858685

Biofrontera Inc. is a United States-based biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical products for dermatological conditions, with a focus on photodynamic therapy (PDT). The company's products include Ameluz and the BF-RhodoLED and RhodoLED XL lamp series, collectively known as the "RhodoLED Lamps." These products are used to treat actinic keratosis (AK), a common skin condition characterized by pre-cancerous lesions. Biofrontera Inc. generates revenue by selling its products directly to dermatology offices and groups through its national commercial team. The company was formed in 2015 as a Delaware corporation and a wholly owned subsidiary of Biofrontera AG, a German stock corporation. Biofrontera Inc. completed its initial public offering in 2021. Effective June 1, 2024, the company assumed control of all clinical trials for Ameluz in the United States, managing costs and trial efficiency through Discovery, its wholly owned subsidiary formed in Germany in 2022. Research and development programs focus on expanding the label for Ameluz and enhancing the capabilities of the RhodoLED Lamps to support PDT growth and meet dermatologists' needs. On October 20, 2025, Biofrontera Inc. acquired all rights in the United States to Ameluz and RhodoLED from the Biofrontera Group through an Asset Purchase Agreement and an Earnout Agreement. On November 6, 2025, the company completed the sale of the intangible asset related to its Xepi product line.

Biofrontera Inc. (NASDAQ:BFRI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for BFRI at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Biofrontera Inc. Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$41.7M
Net Income
-$10.54M
Diluted EPS
-$1.04
Op. Cash Flow
-$13.36M
Free Cash Flow
-$13.36M
Operating Income
-$11.35M
Cash & Equivalents
$6.39M
Debt / Equity
0.00×
Net Margin
-25.3%
Shares Outstanding
11.65M sh
Source: 10-K · filed 2026-03-19 · accession 0001493152-26-011625
$0.5401 +1.91% today
52-week range · as of 2026-11-20 $0.53 – $1.66
Market cap
$9.51M
Volume
196.1K (1.0× avg)
3-mo avg 199.1K
Live data · 2026-11-22 03:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BFRI - Filings & News (Page 2)

BFRI
Jan 07, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7712
Real-time Price: $0.5401 info
Change: -$0.2311 (-30%) info
Market Cap: $9.513M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets